Updated Research Report - Significant Progress

Marina del Rey, CA - January 10, 2017.  We initiated Biotricity (BTCY) coverage in July 2016. Today, we provide you you with an update research report to update you on the significant progress of Biotricity. BTCY has consitently received broad coverage by major print media in the general and medical press and has been covered by several other third party financial analysts. These analysts established a target price between $4.20 and $6.00 per share. SWI is currently discussing the Company's projections with the CEO and will publish its findings in the weeks to follow We believe that the medical experts are beginning to recognize that BTCY is in the advanced stage of the development process for its medical grade "wearable" remote monitoring solution. "BioFlux" will provide increased medical grade data precision and real time remote monitoring that is easy to use and provides significant financial benefits for the medical practitioner. Biotricity is planning to begin commercialization of the product during the first half of 2017. BioFlux - A high-precision wearable ECG device and proprietary software for advanced Mobile Cardiac Telemetry (MCT)  Provides real-time remote data, monitored and read 24/7 at $850 per read for up to 30 consecutive days with clinical accuracy.  Designed to leverage Insurance Reimbursement - Recurring reimbursement to doctors, hospitals and IDTFs Bioflux’s pay-per-use strategy, with no fee for device purchases  Partnerships with Canada NRC CNRC, Alberta Health Services and the University of Calgary Limited number of Competitors Compliant with Insurance Billing Codes - Recurring Business Model Incorporates technology that is future-ready; form and function enables opportunities adjacent to the MCT market Analyst target between $4.50 to $6.00 a share

Mobile Cardiac Telemetry - An Underserved Market

Download Research Report #2 Here

Rainer Poertner - Chief Analyst

StockWatchIndex  and SWI Research (SWI) are not registered investment advisers and the information  provided herein or any other SWI publication is not to be construed as personal financial advice, or a solicitation to buy or sell stock. SWI makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in its publications or on its web sites. Some of the published information has been provided by the companies covered, generated by publicly available sources, or what SWI deems to be reliable third party entities, but SWI does not guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or  warrant any results from use of the information. Readers are encouraged to consult their personal financial adviser before making any decisions to buy, sell or hold any securities mentioned herein. StockWatchIndex is not responsible for any error, mistake or shortcoming that may be occasioned at the time of publishing of the information in this publication, any other SWI publication, or its web sites and is not obligated to update and/or correct information. No liability is accepted by StockWatchIndex whatsoever for any direct, indirect or consequential loss arising from the use of the information. SWI expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information provided. SWI has been engaged by biotricity top advertise this report and has the right to purchase warrants at fair market value for the publication of the information herein. The included information is subject to change without notice. Please visit  www.swiresearch.com/#!legal-ease/lmvw1   for a full text of our Disclaimer, Privacy policy and Terms of Use.